Adjunctive Isradipine for the Treatment of Bipolar Depression
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study investigates the medication isradipine, which is currently approved by the FDA to
treat high blood pressure, in the treatment of depression in bipolar disorder. Isradipine or
placebo (contains no active medication) will be used as an "add-on" to lithium, valproate,
and/or atypical antipsychotics for individuals currently experiencing a major depressive
episode. Our hypothesis is that isradipine will be superior to placebo in improving
depressive symptoms.